Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...